Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. CRWV
8. CME
9. HUMA
10. NVDA

Go back to Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
(NASDAQ: APVO) Delayed: 4.86 +0.14 (2.97%)
Previous Close $4.72    52 Week High $4.33 
Open $4.74    52 Week Low $1.80 
Day High $4.86    P/E N/A 
Day Low $4.59    EPS $0.00 
Volume 15,811